文献速递前列腺癌男科与性医学

整合致病性变异、多基因风险评分与家族史评估非洲裔男性前列腺癌风险

Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.
PubMed 文献 · Eur Urol · 2025-11-10

研究纳入北美和非洲七国7176例前列腺癌病例和4873例对照,分析37个癌症易感基因致病性变异与前列腺癌风险关联。ATM、BRCA2、CHEK2、HOXB13和PALB2变异见于4%的侵袭性/转移性病例,与侵袭性前列腺癌风险升高显著相关(OR 2.18-5.96,p<0.05)。整合变异状态、多基因风险评分和家族史可细化风险估计,终生绝对风险跨度大。

要点

  • ATM、BRCA2、CHEK2、HOXB13、PALB2变异与侵袭性前列腺癌风险升高相关。
  • 整合变异、多基因风险评分和家族史可细化非洲裔男性前列腺癌风险分层。
  • 变异携带者合并家族史阳性及PRS≥90百分位时风险显著增高。

核心结论

  • 整合致病性变异状态、多基因风险评分和家族史可对非洲裔男性前列腺癌风险进行更精细估计。
  • 非洲裔男性中观察到的前列腺癌风险跨度大,支持未来开展前瞻性研究以制定风险分层筛查方案。

研究设计与样本

  • 分析北美和非洲七国7176例前列腺癌病例和4873例对照。
  • 评估37个癌症易感基因致病性变异与总体、侵袭性和转移性前列腺癌风险的关联。
  • 基于家族史、多基因风险评分和致病性变异携带状态估计终生绝对风险。

主要发现

  • ATM、BRCA2、CHEK2、HOXB13和PALB2变异见于4%的侵袭性/转移性前列腺癌病例。
  • 上述变异与侵袭性前列腺癌风险升高显著相关(OR 2.18-5.96,p<0.05)。
  • 终生绝对风险随变异状态、PRS和家族史变化:总体前列腺癌3.0%-74%,侵袭性0.6%-41%,转移性0.2%-37%。
  • 变异携带者合并家族史阳性且PRS在第90百分位时,总体、侵袭性和转移性前列腺癌风险分别为平均风险个体的7倍、18倍和34倍。

关键数值与推荐

  • ATM、BRCA2、CHEK2、HOXB13、PALB2变异与侵袭性前列腺癌风险相关(OR 2.18-5.96,p<0.05)。
  • 终生绝对风险范围:总体前列腺癌3.0%-74%,侵袭性0.6%-41%,转移性0.2%-37%。
  • 变异携带者+家族史阳性+PRS第90百分位者风险为平均风险个体的7倍(总体)、18倍(侵袭性)、34倍(转移性)。

临床怎么用

  • 对非洲裔男性可整合致病性变异、多基因风险评分和家族史进行个体化前列腺癌风险估计。
  • 识别高风险个体可能有助于在更早年龄启动筛查。

局限性

  • 侵袭性病例的过采样可能限制研究结果向筛查人群的推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The impact of germline pathogenic variants (PVs) in cancer predisposition genes on risk of prostate cancer (PCa) remains understudied in large populations of African ancestry. This study aims to characterize the range of genetic risk of PCa and aggressive disease phenotypes in men of African ancestry. METHODS: We analyzed 7176 PCa cases and 4873 controls from seven countries across North America and Africa to assess the association between PVs in 37 cancer predisposition genes and the risk of overall, aggressive, and metastatic PCa. Genes significantly associated with PCa risk were used to estimate lifetime absolute risk based on family history, polygenic risk score (PRS), and PV carrier status. KEY FINDINGS AND LIMITATIONS: PVs in ATM, BRCA2, CHEK2, HOXB13, and PALB2 were presented in 4% of aggressive/metastatic PCa cases and were significantly associated with an increased risk of aggressive PCa (odds ratio 2.18-5.96, p < 0.05). Lifetime absolute risk varied widely depending on PV carrier status, PRS, and family history, ranging from 3.0% to 74% for overall PCa, 0.6% to 41% for aggressive PCa, and 0.2% to 37% for metastatic PCa. PV carriers with a positive family history and a PRS in the 90th percentile had seven, 18, and 34 times the risks of overall, aggressive, and metastatic PCa, respectively, compared with average-risk individuals. Oversampling of aggressive cases may limit the generalizability of these findings to screening populations. CONCLUSIONS AND CLINICAL IMPLICATIONS: Integration of PV status, PRS, and family history enables more refined PCa risk estimates. The wide range of PCa risk observed among men of African ancestry in our study supports future prospective studies in the development of risk-stratified cancer screening programs to identify high-risk individuals who may benefit from screening at an earlier age.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chen F, Sheng X, Wang A, et al. Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry. Eur Urol. 2025. PMID: 41219045. doi:10.1016/j.eururo.2025.09.4161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。